Chemotherapy of metastatic testicular germ cell tumors: Relationship of histologic response to size reduction and changes in tumor markers

International Journal of Urology

Volumn 5, Issue 1, 1998, Pages 74-79

  Koshida, Kiyoshi ^a   Kadono, Yoshifumi ^a   Konaka, Hiroyuki ^a   Kitagawa, Yasuhide ^a   Imao, Tetsuya ^a   Kobayashi, Tadahiro ^a   Kunimi, Kazuto ^a   Uchibayashi, Tadao ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Testicular cancer; Tumor marker

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; TUMOR MARKER; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0031883766     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00243.x     Document Type: Article

References (23)

1. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fosså SD, Wilkinson PM, Kaye SB, Newlands ES, Cook PA.The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 1992;10:85-94.
2. Gerl A, Clemm C, Schmeler N, Hartenstein R, Lamerz R, Wilmanns W. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer 1996;74:1280-1285.
3. The International Germ Cell Cancer Collaborative Group. International germ cell consensus classification. A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
4. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120-126.
5. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50:5904-5910.
6. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994;73:2520-2526.
7. Broun ER, Craig R, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH. Long term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Int Med 1992;117:124-128.
8. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1992;69:550-556.
9. Nichols, CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994;21(suppl 12):102-108.
10. Koshida K, Nishino A, Yamamoto H, Uchibayashi T, Naito K, Hisazumi H, Hirano K, Hayashi Y, Wahren B, Andersson L. The role of alkaline phosphatase isoenzymes as tumor markers for testicular germ cell tumors. J Urol 1991;146:57-60.
11. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE. Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 1982;128:708-711.
12. Uchibayashi T, Egawa M, Hisazumi, H, Hasegawa T, Tanaka T, Sasaki T. In vitro chemosensitivity test for human genitourinary tumors using collagen gel matrix. Eur Urol 1993;24:267-270.
13. Peckham MJ, Barrett A, Liew KH.The treatment of metastatic germ cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47:613-619.
14. Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer 1985;56:2411-2415.
15. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 1987;316:1435-1440.
16. Dearnaley DP, Horwich A, A'Hern R, Nicholls J, Jay G, Hendry WF, Peckham MJ. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 1991;27:684-691.
17. Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P. Correlation of computerized tomographic changes and histologic findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176-1179.
18. Fosså SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky E. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569-573.
19. Schultz SM, Einhorn LH, Conces DJJ, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989;7:1497-1503.
20. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Matzer RJ. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14: 454-460.
21. Broun ER, Nichols CR, Turns M, Williams SD, Locher PJ, Roth BJ, Lazarus HM, Einhorn LH. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73:1716-1720.
22. Rodenhuis S, van der Wall E, ten Bokkel Huinink WW, Schornagel JH, Richel DJ, Vlasveld LT. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest 1995;13: 355-362.
23. Margolin K, Doroshow JH, Ann C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G,Tetef M. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996;14:2631-2637.